Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
16.06
-0.52 (-3.14%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
95
Market Cap
218.76M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Cellectis | 63.82M |
| Arcturus Therapeutics Holdings | 29.37M |
| Tonix Pharmaceuticals Holding | 29.10M |
| Alector | 13.86M |
| Innate Pharma | 10.57M |
| Camp4 Therapeutics | 4.22M |
IMUX News
- 3 days ago - Immunic Earnings release: Q2 2026 - Filings
- 3 days ago - Immunic Quarterly report: Q2 2026 - Filings
- 3 days ago - Immunic reports Q2 EPS (80c), consensus ($1.16) - TheFly
- 3 days ago - Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 4 days ago - Immunic Appoints Elena Ridloff to Board of Directors - PRNewsWire
- 4 weeks ago - Immunic Slides: Investor presentation - Filings
- 5 weeks ago - Immunic to Participate in Investor Conferences in July - PRNewsWire
- 2 months ago - Immunic to Participate in Investor, Industry and Scientific Conferences in June - PRNewsWire